Alexion Pharmaceuticals, Inc. (ALXN)

[surf1944]

6:36AM Alexion Pharma beats by $0.13, reports revs in-line; co raises and guides FY12 EPS above consensus, raises rev guidance, in-line (ALXN) 100.94 : Reports Q3 (Sep) earnings of $0.60 per share, $0.13 better than the Capital IQ Consensus Estimate of $0.47; revenues rose 44.2% year/year to $294.1 mln vs the $294.02 mln consensus. Co raises and issues upside guidance for FY12, sees EPS of $1.99-2.04 vs. $1.89 Capital IQ Consensus Estimate and above prior guidance of $1.78-1.88; sees FY12 revs of toward higher end of $1.12-1.13 bln vs. $1.13 bln Capital IQ Consensus Estimate, which is above prior guidance of $1.110-1.125 bln. The upward revision reflects continued global growth of Soliris in PNH and growth from the ongoing launch of Soliris in aHUS. Revenue performance for the quarter reflected steady additions of new patients with paroxysmal nocturnal hemoglobinuria commencing Soliris therapy in Alexion's core territories of the US, Western Europe and Japan, as well as in new countries. Revenues were further augmented by an increasing number of new patients with atypical hemolytic uremic syndrome commencing Soliris treatment.